Aby J. Mathew Sells 536 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 536 shares of BioLife Solutions stock in a transaction dated Monday, July 7th. The shares were sold at an average price of $22.27, for a total transaction of $11,936.72. Following the transaction, the executive vice president owned 352,582 shares of the company's stock, valued at $7,852,001.14. This represents a 0.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

BioLife Solutions Stock Performance

BLFS stock traded up $0.73 during mid-day trading on Thursday, hitting $23.06. The company had a trading volume of 108,173 shares, compared to its average volume of 419,848. The firm has a market cap of $1.10 billion, a PE ratio of -79.58 and a beta of 1.79. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.74 and a current ratio of 4.73. BioLife Solutions, Inc. has a 12 month low of $18.70 and a 12 month high of $29.55. The stock's fifty day moving average price is $22.42 and its two-hundred day moving average price is $24.39.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.07. The company had revenue of $23.94 million for the quarter, compared to analyst estimates of $22.22 million. BioLife Solutions had a negative net margin of 11.81% and a negative return on equity of 0.66%. On average, analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioLife Solutions

Hedge funds have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC purchased a new position in BioLife Solutions during the fourth quarter valued at approximately $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in BioLife Solutions in the 4th quarter worth approximately $31,000. State of Wyoming grew its stake in BioLife Solutions by 353.1% in the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock worth $44,000 after buying an additional 1,490 shares in the last quarter. US Bancorp DE grew its stake in BioLife Solutions by 243.7% in the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock worth $49,000 after buying an additional 1,528 shares in the last quarter. Finally, 1620 Investment Advisors Inc. grew its stake in BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after buying an additional 675 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BLFS. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a research report on Tuesday, May 13th. Wall Street Zen lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, BioLife Solutions presently has an average rating of "Moderate Buy" and an average price target of $31.17.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.